Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2026)
Fortrea Holdings' (FTRE) quarterly Asset Writedowns and Impairment came in at $1.0 million in Q2 2026, down 99.68% YoY from $309.1 million in Q2 2025, and down 66.67% on a QoQ basis from $3.0 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 4 years of Asset Writedowns and Impairment data on file, last reported at $1.0 million in Q2 2026.
- Quarterly Asset Writedowns and Impairment fell 99.68% year-over-year to $1.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.0 million (down 99.5% YoY) and the FY2025 annual result came in at $797.9 million, up 3224.58% from the prior year.
- Asset Writedowns and Impairment retreated to $1.0 million in Q2 2026, from $3.0 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $488.8 million in Q1 2025 to a low of $1.0 million in Q2 2026.
- A 4-year average of $108.2 million and a median of $17.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment jumped 2433.61% — and 2026, when it plunged 99.68%.
- Tracing FTRE's Asset Writedowns and Impairment over 4 years: stood at $5.9 million in 2023, then surged by 106.78% to $12.2 million in 2024, then jumped by 2433.61% to $309.1 million in 2025, then sank by 99.68% to $1.0 million in 2026.
- The last three Asset Writedowns and Impairment figures came in at $1.0 million (Q2 2026), $3.0 million (Q1 2026), and $309.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Jun 30, 2025 | 309.10 Mn |
| Mar 31, 2025 | 488.80 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Dec 31, 2023 | 5.90 Mn |
| Sep 30, 2023 | 21.90 Mn |